Clinical Trial: A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

U.S., May 19 -- ClinicalTrials.gov registry received information related to the study (NCT07592689) titled 'A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)' on May 12.

Brief Summary: A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Major Depressive Disorder - Ascend

Study Start Date: May 10

Study Type: INTERVENTIONAL

Condition: Major Depressive Disorder

Intervention: OTHER: Placebo

A substance that is designed to have no therapeutic value

DRUG: DT120

A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)

Recruitment Status: RECRUITING

Sponsor: Definium Therapeutic...